A study looking at selumetinib for non small cell lung cancer

This study is looking at a new drug called selumetinib for non small cell lung cancer. This is for non small cell lung cancer (NSCLC) that has spread into surrounding tissues (locally advanced) or has spread to another part of the body (advanced).

Doctors can treat locally advanced and advanced NSCLC with chemotherapy. One combination of chemotherapy that doctors use is gemcitabine or pemetrexed with either cisplatin or carboplatin. This chemotherapy helps but doctors are always looking for ways to improve treatment.

Selumetinib is a type of anticancer therapy called a cancer growth blocker. It stops signals that cancer cells use to divide and grow.

The researchers think that combining selumetinib with gemcitabine or pemetrexed and cisplatin or carboplatin may be better than gemcitabine or pemetrexed and cisplatin or carboplatin alone.

The aims of this trial are to find out

• How well the combination of selumetinib with gemcitabine or pemetrexed and cisplatin or carboplatin works for NSCLC

• What the side effects are

• How safe it is